We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RRX:NYSERegal Rexnord Corporation Analysis

Data as of 2026-09-05 - not real-time

$162.86

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Regal Rexnord Corporation is priced at $162.86, and its moving averages give no clean directional read — the structure is neutral. It has lost 23.4% over the past 30 days. RSI sits at 38.0, which reads as approaching oversold, and MACD momentum is bullish. The recent range runs from support at $154.06 up to resistance at $179.35.
On valuation the read is fair — earnings multiple of 33.4 versus a 28.5 sector average, above the peer group. Consensus targets land 52.9% above where the shares trade now. Revenue is growing at 4.2% on a 5.3% profit margin. The 0.86% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 68.5%, a beta of 2.16 and a maximum drawdown of 34.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.

Top Market Events

Regal Rexnord NYSE:RRX just posted its strongest order growth in years in its August 5 earnings release, with a new...Regal Rexnord Corp RRX reports robust order growth and AMC segment strength, but lowers full-year margin guidance amid...Industrials products and automation company Regal Rexnord NYSE:RRX missed Wall Street’s revenue expectations in Q2...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Trading below the 200-day average of 187.56
  • MACD momentum is positive
  • 30-day price change of -23.4%

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 33.4 versus sector average of 28.5
  • Trading below the 200-day average of 187.56
  • Analyst targets imply +52.9% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • P/E of 33.4 versus sector average of 28.5
  • Analyst targets imply +52.9% versus the current price
  • 30-day volatility of 68.5%

Key Metrics & Analysis

Financial Health

Revenue Growth4.20%
Profit Margin5.35%
P/E Ratio33.4
ROE4.77%
ROA3.24%
Debt/Equity68.84
P/B Ratio1.6
Op. Cash Flow$556.9M
Free Cash Flow$455.2M
Industry P/E28.5

Technical Analysis

TrendNeutral
RSI38.0
Support$154.06
Resistance$179.35
MA 20$166.30
MA 50$192.11
MA 200$187.56
MACDBullish
VolumeStable
Fear & Greed Index95.48

Valuation

Fair Value$38.66
Target Price$249.00
Upside/Downside52.89%
GradeFair
TypeGrowth
Dividend Yield0.86%

Risk Assessment

Beta2.16
Volatility68.46%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.